J. B. Chemicals & Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
J. B. Chemicals & Pharmaceuticals has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 17.1% per year. J. B. Chemicals & Pharmaceuticals's return on equity is 18.9%, and it has net margins of 15.2%.
Key information
14.5%
Earnings growth rate
15.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 17.1% |
| Return on equity | 18.9% |
| Net Margin | 15.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How J. B. Chemicals & Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 33,848 | 5,141 | 7,687 | 0 |
| 30 Sep 23 | 33,330 | 4,866 | 7,554 | 0 |
| 30 Jun 23 | 32,607 | 4,471 | 7,427 | 0 |
| 31 Mar 23 | 31,493 | 4,098 | 7,278 | 0 |
| 31 Dec 22 | 30,115 | 4,071 | 6,511 | 0 |
| 30 Sep 22 | 28,195 | 3,848 | 6,322 | 0 |
| 30 Jun 22 | 26,031 | 3,715 | 6,020 | 0 |
| 31 Mar 22 | 24,242 | 3,854 | 5,662 | 0 |
| 31 Dec 21 | 23,281 | 4,011 | 4,943 | 0 |
| 30 Sep 21 | 22,757 | 4,713 | 4,596 | 0 |
| 30 Jun 21 | 21,262 | 4,474 | 4,352 | 0 |
| 31 Mar 21 | 20,425 | 4,480 | 4,258 | 0 |
| 31 Dec 20 | 19,576 | 3,975 | 4,247 | 0 |
| 30 Sep 20 | 18,381 | 3,097 | 4,224 | 0 |
| 30 Jun 20 | 18,509 | 3,295 | 4,183 | 0 |
| 31 Mar 20 | 17,747 | 2,720 | 4,068 | 0 |
| 31 Dec 19 | 17,501 | 2,686 | 4,060 | 0 |
| 30 Sep 19 | 17,035 | 2,521 | 3,959 | 0 |
| 30 Jun 19 | 16,824 | 2,098 | 3,926 | 0 |
| 31 Mar 19 | 16,432 | 1,935 | 3,820 | 0 |
| 31 Mar 18 | 14,084 | 1,383 | 3,212 | 0 |
| 31 Mar 17 | 13,443 | 1,841 | 2,798 | 0 |
| 31 Mar 16 | 12,104 | 1,625 | 2,282 | 0 |
| 31 Mar 15 | 11,442 | 1,004 | 2,120 | 0 |
| 31 Mar 14 | 10,219 | 615 | 3,072 | 0 |
Quality Earnings: 506943 has high quality earnings.
Growing Profit Margin: 506943's current net profit margins (15.2%) are higher than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506943's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: 506943's earnings growth over the past year (26.3%) exceeds its 5-year average (14.5% per year).
Earnings vs Industry: 506943 earnings growth over the past year (26.3%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 506943's Return on Equity (18.9%) is considered low.